.The Bellvitge Institute for Biomedical Research (IDIBELL) is looking for ambitious and highly motivated scientists with an outstanding track record of scientific accomplishments to apply for independent tenure-track Group Leader research positions in the Regenerative Medicine Program. The deadline for applications is December 31st, 2023.Successful candidates will benefit from:A vibrant, international, and collaborative environmentA flexible start-up package to set up the lab, the initial team, and to cover lab expensesAccess to state-of-the-art research facilitiesTraining in collaboration with other institutionsTailored support in raising competitive fundsA creative and collaborative environment to nurture excellenceBellvitge Biomedical Research Institute (IDIBELL) is one of the most dynamic health research institutes in Spain with more than 1,200 researchers in the fields of basic, translational, and clinical research who strive to attain significant improvements in human health. The institute was established in 2004 in L'Hospitalet de Llobregat, southern Barcelona metropolitan area. IDIBELL manages the research activities of Bellvitge University Hospital, the Catalan Institute of Oncology (Hospitalet), the University of Barcelona (Bellvitge Campus), and its own researchers. Research is structured into four thematic areas (cancer, neurosciences, translational medicine, and regenerative medicine). IDIBELL's vision is turning Bellvitge Health Area into a health hub of excellence, thanks to its combination of comprehensive medical care, research experience, and unique economic environment. IDIBELL is an accredited Health Research Institute by the Carlos III Institute of Health.The Regenerative Medicine Program of IDIBELL integrates fundamental and translational research on the use of cells and tissues to treat degenerative diseases. The Program is currently composed of 8 independent research groups whose activities span broad areas of science, including stem cell biology, developmental biology, regeneration and aging, development of advanced therapies, and molecular mechanisms of disease. Researchers within the Regenerative Medicine Program of IDIBELL employ experimental systems that range from zebrafish and mice to human pluripotent stem cells and organoids. The Program also hosts the Barcelona Stem Cell Bank, a node of the Carlos III Institute of Health's Spanish Cell Bank, which generates, registers, and banks human iPS cell lines.The Regenerative Medicine Program of IDIBELL is a key part of the Program for the Clinical Translation of Regenerative Medicine in Catalonia (P-CMR[C]), a transversal action in the Catalan environment that brings together the relevant stakeholders for advancing the clinical translation of strategies of regenerative medicine based on the use of pluripotent stem cells